血必净注射液治疗急性呼吸窘迫综合征的疗效观察

目的:探讨血必净注射液治疗急性呼吸窘迫综合征的疗效。方法:选取2010年1月—2011年1月收治的急性呼吸窘迫综合征患者共100例,以随机抽样法分为治疗组和对照组各50例,全部患者均进行常规的治疗,治疗组加用血必净注射液。结果:治疗3 d后,治疗组患者的二氧化碳分压(PaCO2)、氧合指数(PaO2/FiO2)及血氧饱和度(SaO2)水平均明显高于对照组(P<0.05);治疗1周后,治疗组患者的心率、呼吸频率、C反应蛋白、白细胞计数、IL-1、IL-6及TNF-α水平均明显低于对照组(P<0.05);治疗组患者机械通气时间、平均重症监护(ICU)时间及死亡率均明显低于对照组(P<0.05)。结论:采用血必净注射液治疗急性呼吸窘迫综合征的临床疗效确切,值得在临床上推广应用。

Efficacy of Xuebijing Injection for Acute Respiratory Distress Syndrome

OBJECTIVE: To evaluate the efficacy of Xuebijing injection for acute respiratory distress syndrome(ARDS).METHODS: A total of 100 patients with ARDS admitted to our hospital between Jan.2010 and Jan.2011 were randomly assigned to either trial group or control group,of 50 each.All the patients received routine therapy,while the trial group received add-on Xuebijing injection.RESULTS: After 3-day treatment,PaCO2,PaO2/FiO2 and SaO2 levels in the trial group were significantly higher than in control group(P<0.05);after 1-week treatment,the heart rate,respiratory frequency,C-reactive protein,white blood count,IL-1,IL-6 and TNF-α levels in the trial group were all significantly lower than in control group(P<0.05);the mechanical ventilation time,mean time in ICU and death rate in the trial group were also significantly lower than in control group(P<0.05).CONCLUSION: Xuebijing injection has proved efficacy for acute respiratory distress syndrome(ARDS),thus it is worthy of clinical use.